From $3M to $1.9B: Glax­o­SmithK­line in­serts dis­card­ed Gilead drug in­to late-stage port­fo­lio, buy­ing out the turn­around crew at Sier­ra

As a drug for­mer­ly aban­doned by Gilead fi­nal­ly looks set to com­plete its tor­tu­ous jour­ney to­ward FDA ap­proval, Glax­o­SmithK­line is shelling out $1.9 bil­lion to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER